Literature DB >> 18430393

Over-suppression of bone turnover: does it exist?

Juliet Compston1.   

Abstract

Bone-turnover suppression is central to the therapeutic benefit of many interventions used to prevent osteoporotic fractures. There are theoretical concerns that long-term suppression may have adverse effects on bone strength, although at present no direct evidence exists that this happens. Nevertheless, further research is required to establish the optimal duration of treatment with antiresorptive agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18430393     DOI: 10.1007/s11914-007-0014-0

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  43 in total

Review 1.  Molecular markers of bone turnover: biochemical, technical and analytical aspects.

Authors:  M J Seibel
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

2.  Influence of nonenzymatic glycation on biomechanical properties of cortical bone.

Authors:  D Vashishth; G J Gibson; J I Khoury; M B Schaffler; J Kimura; D P Fyhrie
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

3.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

Authors:  R R Recker; R S Weinstein; C H Chesnut; R C Schimmer; P Mahoney; C Hughes; B Bonvoisin; P J Meunier
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

6.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

7.  Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

Authors:  R Eastell; I Barton; R A Hannon; A Chines; P Garnero; P D Delmas
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

8.  Age-related changes in the collagen network and toughness of bone.

Authors:  X Wang; X Shen; X Li; C Mauli Agrawal
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Authors:  J Adachi; A Cranney; C H Goldsmith; W G Bensen; F Bianchi; A Cividino; G L Craig; E Kaminska; R J Sebaldt; A Papaioannou
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

10.  Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate.

Authors:  Juliet E Compston; Shobna Vedi; Stephen Kaptoge; Ego Seeman
Journal:  J Bone Miner Res       Date:  2007-07       Impact factor: 6.741

View more
  2 in total

Review 1.  Is bone quality associated with collagen age?

Authors:  D J Leeming; K Henriksen; I Byrjalsen; P Qvist; S H Madsen; P Garnero; M A Karsdal
Journal:  Osteoporos Int       Date:  2009-03-28       Impact factor: 4.507

2.  Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort).

Authors:  Eduardo Kanterewicz; Pilar Peris; Emma Puigoriol; Aina Yáñez; Pau Rosique; Luis Del Rio
Journal:  J Bone Miner Metab       Date:  2012-12-08       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.